HMPL 002

Drug Profile

HMPL 002

Alternative Names: HMPL-002

Latest Information Update: 04 Feb 2009

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Chemosensitisers; Radiation-sensitising agents; Radiosensitisers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Head and neck cancer
  • Suspended Non-small cell lung cancer

Most Recent Events

  • 04 Feb 2009 Suspended - Phase-II for Non-small cell lung cancer in China (PO)
  • 04 Feb 2009 Suspended - Phase-I for Head and neck cancer in USA (PO)
  • 04 Feb 2009 Interim efficacy & adverse events data from a phase II trial in Non-small cell lung cancer released by Chi-Med
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top